New EHR interface expected to boost VA, DoD interoperability

A new EHR system interface is geared to help the Department of Veterans Affairs share data with the Department of Defense's EHR system and increase interoperability between the agencies, according to a report from FCW.

Called the Enterprise Health Management Platform, the interface is a web-based system that relies on applications and widgets to provide data regarding patients' allergies, clinical visits, lab results, medical conditions, prescribed medications and vital signs.

The interface also will allow VA providers to access and update patient records at different facilities. Providers will be able to customize the way they view patient data and use the system to track patients' specific conditions and view short-term and long-term care plans.

The system will have to work with the vendor supplying the new DoD EHR system, which will be announced this summer.

 

According to reports, pilots of the new VA system will be launched in Oregon and Texas in July with all VA facilities expected to have access to the program by 2017 The VA plans to phase out its current interface by 2020.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.